ALT-B4 / Alteogen - LARVOL DELTA

AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets (AstraZeneca Press Release) - "AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca."

Licensing / partnership • Oncology

Alteogen, Subcutaneous Injection ADC Patent Application… “Safe and Better Therapeutic Effect” [Google translation] (News1 Korea) - "Alteogen...announced on the 2nd that it has filed a domestic priority application for a subcutaneous injection (SC) formulation of an antibody drug conjugate (ADC)...Alteogen has been focusing on the possibility of developing a SC formulation ADC by incorporating its platform technology, ‘ALT-B4’, to overcome the limitations of existing ADC treatments....'This patent can strengthen the competitiveness of our own pipeline, 'ALT-P7,' which targets the HER2 receptor.'"

Patent • Breast Cancer • Oncology • Solid Tumor